

International AIDS Vaccine Initiative



125 Broad Street, 9th Floor
New York, NY 10004
(212) 847-1111
www.iavi.org



Mission

The International AIDS Vaccine Initiative (IAVI) is a global nonprofit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.

Strategy/Approach

IAVI is a product development partnership (PDP) that collaborates with more than 100 academic, industry, and government organizations around the world to research and develop AIDS vaccines. It serves as a bridge between sectors and provides its partners with support in translational research.

Founded in 1996, IAVI works with partners in 25 countries to research, design, and develop AIDS vaccine candidates. The organization also conducts policy analysis and serves as an advocate for the AIDS vaccine field. It supports a comprehensive approach to addressing HIV and AIDS that balances the expansion and strengthening of existing HIV prevention and treatment programs with targeted investments in the design and development of new tools to prevent HIV.

IAVI's efforts are aimed at:

- **Accelerating the development of AIDS vaccines** by identifying opportunities and gaps in the field and ensuring that IAVI invests its resources in areas that add the most value.
- **Harnessing partnerships** to expand the diversity and number of novel AIDS vaccine candidates.
- **Building support for AIDS vaccine development** through global R&D collaboration and policy advocacy.

Research Portfolio

IAVI's R&D team designs and develops HIV vaccine candidates and conducts vaccine trials and related epidemiological research in partnership with researchers across the globe. IAVI is advancing a distinct portfolio of preventive HIV vaccine candidates through its research and development programs, taking two primary approaches to design candidates:

- Blocking HIV infection by engaging the antibody response
- Destroying infected cells via cell mediated immunity

Key initiatives include:

- **Neutralizing Antibody Consortium** – Launched in 2002 to study the molecular structure and biochemistry of known broadly neutralizing antibodies and to use this information to design (reverse engineer) potentially powerful AIDS vaccine candidates.

- **Innovation Fund** – Funded in part by the Bill & Melinda Gates Foundation, it surveys the biotech universe to identify promising technologies that are being developed for non-HIV applications and provides funding for short-term, high-risk, proof-of-concept studies that evaluate their applicability to AIDS vaccine development.
- **Clinical Research Center network** – A network of independent but interconnected research centers in five sub-Saharan African countries (Kenya, Rwanda, South Africa, Uganda, and Zambia) where HIV vaccine candidates are tested and epidemiological studies that inform the design of candidates are conducted.
- **Human Immunology Laboratory** – Established in 2001 at the Imperial College of Science, Technology and Medicine in London, it serves as a hub for IAVI's vaccine development partnerships.

Partnership Practices

Government research institutions, academic laboratories, pharmaceutical and small biotech companies, clinical research centers, and contract manufacturing organizations are all among the scientific institutions IAVI works with in its efforts to speed the development of vaccines. IAVI's partnerships bridge the gap between these sectors through mechanisms such as the **Neutralizing Antibody Consortium** and the **Innovation Fund**.

IAVI is currently working to expand the number and types of collaborations it engages in globally to capitalize on the existing scientific capabilities of a greater number of nations and to leverage international funding opportunities. Over the past 15 years, IAVI has collaborated with scores of researchers around the world, most notably in Africa and India. Recently, it has announced a program in immunogen design with the government of India and facilitated the establishment of an HIV vaccine design and development partnership between India and South Africa.

IAVI partners with biotech and pharmaceutical companies.

It works to harness the expertise and resources of industry to design and develop vaccine candidates, in part through partnerships in which IAVI assumes much of the risk associated with the early stages of such efforts. IAVI's partnerships with pharmaceutical companies bring to HIV vaccine R&D the industry's vast candidate screening libraries and compounds that boost the immune response to vaccines, known as adjuvants. They also tap the industry's extensive stores of experience and expertise in the R&D process. For example:

- **Theraclone Sciences** – Received a grant from IAVI’s Innovation Fund to adapt its antibody isolation technology to HIV vaccine research. Resulted in the isolation of more than 20 new broadly neutralizing antibodies to HIV.
- **Algonomics** – This partnership resulted in a new in vitro test to predict the immunogenicity of HIV vaccine antigens, a capability that has the potential to help accelerate AIDS vaccine development.

Financials

IAVI is a 501(c)(3) nonprofit organization. The latest financial information available is from 2012.¹

Year ending 12/31/12:

- Revenue: \$61,459,050
- Assets: \$90,186,843 (market value)
- Grants: \$11,917,738
- Gifts received: \$59,232,675
- Expenditures: \$69,073,411

Key Accomplishments

- Together with nonprofit, public- and private-sector partners, designed 22 AIDS vaccine candidates, evaluating 13 of them in early-stage human trials in 11 countries in Asia, Africa, Europe, and North America.
- Established the Clinical Research Center network in Africa to address lack of infrastructure to test clinical vaccine candidates in the developing world. Also established programs for AIDS vaccine design and development with the government of India.
- Since launching the Neutralizing Antibody Consortium in 2002, identified dozens of novel broadly neutralizing antibodies to support the rational design of immunogens and advance progress toward the next generation of AIDS vaccines.

Leadership

The initiative is governed by a **Board of Directors** and counseled by a **Scientific Advisory Committee** and **Policy Advisory Committee**. It is managed by leadership staff around the world, and a New York-based executive staff.

- **President and CEO:** Margaret McGlynn
- **SVP and Chief Scientific Officer:** Wayne Koff, wkoff@iavi.org
- **SVP and General Counsel:** Labeeb Abboud, labboud@iavi.org
- **Vice President, External Relations:** Jane Waterman

¹ Information obtained from GuideStar. <http://www.guidestar.org/organizations/13-3870223/international-aids-vaccine-initiative.aspx>, March 2014.